CD4+ Cancer Research Results

CD4+, CD4+ T Cells: Click to Expand ⟱
Source:
Type:
CD4+ T cells are T lymphocytes that express T cell receptors (TCRs).
Majority of cancer immunotherapies focus on harnessing the anti-tumour CD8+ cytotoxic T cell response, the potential role of CD4+ ‘helper’ T cells has largely remained in the background. multifaceted role of CD4+ T cells in the anti-tumour immune response.
CD4+ T cells play a critical role in developing and sustaining effective anti-tumour immunity, even in cancer immunotherapies specifically designed to activate a CD8+ CTL response.
Scientific Papers found: Click to Expand⟱
346- AgNPs,  RSQ,    Investigating Silver Nanoparticles and Resiquimod as a Local Melanoma Treatment
- in-vivo, Melanoma, SK-MEL-28 - in-vivo, Melanoma, WM35
ROS↑, Ca+2↝, Casp3↑, Casp8↑, Casp9↑, CD4+↑, CD8+↑, tumCV↓, eff↓, *toxicity↓,
542- Akk,  immuno,    Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
CD4+↑, CXCc↑, PD-1↝,
315- Api,    Apigenin: Selective CK2 inhibitor increases Ikaros expression and improves T cell homeostasis and function in murine pancreatic cancer
- vitro+vivo, PC, Panc02
CK2↓, CD4+↑, CD8+↑, Ikaros↑,
1205- Caff,  immuno,    Caffeine-enhanced anti-tumor activity of anti-PD1 monoclonal antibody
- in-vivo, Melanoma, B16-F10
OS↑, CD4+↑, CD8+↑, AntiTum↑, TNF-α↑, IFN-γ↑,
6030- CGA,    Chlorogenic acid induces apoptosis, inhibits metastasis and improves antitumor immunity in breast cancer via the NF‑κB signaling pathway
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-453 - in-vitro, Nor, MCF10
NF-kB↓, AntiTum↑, tumCV↓, TumCP↓, Apoptosis↑, TumCMig↓, TumCI↓, EMT↓, TumCG↓, OS↑, TumMeta↓, CD4+↑, CD8+↑, Imm↑,
1033- CHr,    Chrysin inhibits hepatocellular carcinoma progression through suppressing programmed death ligand 1 expression
- vitro+vivo, HCC, NA
TumCG↓, CD4+↑, CD8+↑, PD-L1↓,
1959- GamB,    Gambogic acid induces GSDME dependent pyroptotic signaling pathway via ROS/P53/Mitochondria/Caspase-3 in ovarian cancer cells
- in-vitro, Ovarian, NA - in-vivo, NA, NA
AntiCan↑, Pyro↑, tumCV?, CellMemb↓, cl‑Casp3↑, GSDME-N↑, ROS?, p‑P53↑, eff↓, MMP↓, Bcl-2↓, BAX↑, mtDam↑, Cyt‑c↑, TumCG↓, CD4+↑, CD8+↑,
2518- H2,    Hydrogen Therapy Reverses Cancer-Associated Fibroblasts Phenotypes and Remodels Stromal Microenvironment to Stimulate Systematic Anti-Tumor Immunity
- in-vitro, BC, 4T1 - in-vitro, Nor, 3T3
TumCD↑, CD4+↑, ROS↓,
1021- HNK,    Honokiol suppress the PD-L1 expression to improve anti-tumor immunity in lung cancer
- in-vivo, Lung, NA
PD-L1↓, T-Cell↑, CD4+↑, CD8+↑, TumCG↓,
7652- IP,    Inulin prebiotic reinforces host cancer immunosurveillance via ɣδ T cell activation
- in-vivo, Melanoma, B16-F10
GutMicro↑, Imm↑, CD4+↑, CD8+↑, TumCG↓,
8237- LCA,    Role of Licochalcone A in Potential Pharmacological Therapy: A Review
- Review, Var, NA
*other↝, *Inflam↓, *Bacteria↓, *antiOx↑, *AntiP↑, *neuroP↑, *glucose↝, *lipid-P↓, PKCδ↓, P70S6K↓, Akt↓, ER Stress↑, Apoptosis↑, Ca+2↑, PI3K↓, mTOR↓, Casp3↑, Bcl-2↓, Cyt‑c↑, BAX↑, cl‑PARP↑, cycD1/CCND1↑, ROS↑, CHOP/DDIT3↑, ERK↑, p38↑, JNK↓, IAP1↓, XIAP↓, survivin↓, cFLIP↓, RIP1↓, EGFR↓, MET↓, HER2/EBBR2↓, p‑4E-BP1↓, PERK↑, eIF2α↑, PD-L1↓, HK2↓, Glycolysis↓, Sp1/3/4↓, FasL↑, MMP↓, ATP↓, TumAuto↑, WEE1↑, P21↑, CDK1↓, TumCCA↑, TumCMig↓, TumCI↓, ABCG2↓, HSP90↓, T-Cell↑, CD4+↑, CD25+↑, FOXP3↑, Imm↝, *Inflam↓, *NF-kB↓, *NRF2↑, *AntiArt↑,
8124- LF,    Inhibition of intestinal polyp growth by oral ingestion of bovine lactoferrin and immune cells in the large intestine
- Trial, CRC, NA
Risk↓, Dose↝, NK cell↑, Neut↑, CD4+↑, Imm↑, APG↓,
1782- MEL,    Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumCG↑, TumMeta↑, ChemoSideEff↓, radioP↑, ChemoSen↑, *ROS↓, *SOD↑, *GSH↑, *GPx↑, *Catalase↑, Dose∅, VEGF↓, eff↑, Hif1a↓, GLUT1↑, GLUT3↑, CAIX/CA9↑, P21↑, p27/CDKN1B↑, PTEN↑, Warburg↓, PI3K↓, Akt↓, NF-kB↓, cycD1/CCND1↓, CDK4↓, CycB/CCNB1↓, CDK4↓, MAPK↑, IGF-1R↓, STAT3↓, MMP9↓, MMP2↓, MMP13↓, E-cadherin↑, Vim↓, RANKL↓, JNK↑, Bcl-2↓, P53↑, Casp3↑, Casp9↑, BAX↑, DNArepair↑, COX2/PTGS2↓, IL6↓, IL8↓, NO↓, T-Cell↑, NK cell↑, Treg lymp↓, FOXP3↓, CD4+↑, TNF-α↑, Th1 response↑, BioAv↝, RadioS↑, OS↑,
221- MFrot,  MF,    Low Frequency Magnetic Fields Enhance Antitumor Immune Response against Mouse H22 Hepatocellular Carcinoma
- in-vivo, Liver, NA
OS↑, TumCG↓, IL6↓, GM-CSF↓, CXCc↓, Macrophages↑, DCells↑, CD4+↑, CD8+↑, IL12↑,
220- MFrot,  MF,    Effect of low frequency magnetic fields on melanoma: tumor inhibition and immune modulation
- in-vitro, Melanoma, B16-F10
OS↑, DCells↑, T-Cell↑, Apoptosis↑, IL1↑, IFN-γ↓, IL10↑, TumCG↓, ROS↑, TumCP↓, TumCCA↑, ChrMod↑, CXCL9↓, CXCL12↓, CD4+↑, CD8+↑,
198- MFrot,  MF,    Biological effects of rotating magnetic field: A review from 1969 to 2021
- Review, Var, NA
AntiCan↑, breath↑, Pain↓, Appetite↑, Strength↑, BowelM↑, TumMeta↓, TumCCA↑, ETC↓, MMP↓, TumCD↑, selectivity↑, ROS↑, Casp3↑, TumCG↓, TumCCA↑, ChrMod↑, TumMeta↓, Imm↑, DCells↑, Akt↓, OS⇅, toxicity↓, QoL↑, hepatoP↑, Pain↓, Weight↑, Strength↑, Sleep↑, IL6↓, CD4+↑, CD8+↑, Ca+2↑, radioP↑, chemoP↑, *BMD↑, *AntiAge↑, *AMPK↑, *P21↓, *P53↓, *mTOR↓, *OS↑, *β-Endo↑, *5HT↓,
3141- VitC,    High-dose Vitamin C inhibits PD-L1 expression by activating AMPK in colorectal cancer
- in-vitro, CRC, HCT116
Glycolysis↓, eff↑, PD-L1↓, AMPK↑, HK2↓, NF-kB↓, Warburg↓, tumCV↓, GLUT1↓, PKM2↓, LDHA↓, CD4+↑, CD8+↑,

Showing Research Papers: 1 to 17 of 17

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 17

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

APG↓, 1,   WEE1↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

ROS?, 1,   ROS↓, 1,   ROS↑, 4,  

Metal & Cofactor Biology(tgid=2) ⓘ

Ikaros↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 1,   ETC↓, 1,   MMP↓, 3,   mtDam↑, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   CAIX/CA9↑, 1,   Glycolysis↓, 2,   HK2↓, 2,   LDHA↓, 1,   PKM2↓, 1,   Warburg↓, 2,  

Cell Death(tgid=5) ⓘ

Akt↓, 3,   Apoptosis↑, 4,   BAX↑, 3,   Bcl-2↓, 3,   Casp3↑, 4,   cl‑Casp3↑, 1,   Casp8↑, 1,   Casp9↑, 2,   cFLIP↓, 1,   CK2↓, 1,   Cyt‑c↑, 2,   FasL↑, 1,   GSDME-N↑, 1,   IAP1↓, 1,   JNK↓, 1,   JNK↑, 1,   MAPK↑, 1,   p27/CDKN1B↑, 1,   p38↑, 1,   Pyro↑, 1,   RIP1↓, 1,   survivin↓, 1,   TumCD↑, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 1,   Sp1/3/4↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

BowelM↑, 1,   ChrMod↑, 2,   tumCV?, 1,   tumCV↓, 3,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   eIF2α↑, 1,   ER Stress↑, 1,   HSP90↓, 1,   PERK↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNArepair↑, 1,   P53↑, 1,   p‑P53↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CDK4↓, 2,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 1,   cycD1/CCND1↑, 1,   P21↑, 2,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

p‑4E-BP1↓, 1,   EMT↓, 1,   ERK↑, 1,   IGF-1R↓, 1,   mTOR↓, 1,   P70S6K↓, 1,   PI3K↓, 2,   PTEN↑, 1,   STAT3↓, 1,   TumCG↓, 8,   TumCG↑, 1,  

Migration(tgid=13) ⓘ

Ca+2↑, 2,   Ca+2↝, 1,   CXCL12↓, 1,   E-cadherin↑, 1,   MET↓, 1,   MMP13↓, 1,   MMP2↓, 1,   MMP9↓, 1,   PKCδ↓, 1,   Treg lymp↓, 1,   TumCI↓, 2,   TumCMig↓, 2,   TumCP↓, 3,   TumMeta↓, 3,   TumMeta↑, 1,   Vim↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↓, 1,   Hif1a↓, 1,   NO↓, 1,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

CellMemb↓, 1,   GLUT1↓, 1,   GLUT1↑, 1,   GLUT3↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD25+↑, 1,   CD4+↑, 17,   COX2/PTGS2↓, 1,   CXCc↓, 1,   CXCc↑, 1,   CXCL9↓, 1,   DCells↑, 3,   FOXP3↓, 1,   FOXP3↑, 1,   GM-CSF↓, 1,   IFN-γ↓, 1,   IFN-γ↑, 1,   IL1↑, 1,   IL10↑, 1,   IL12↑, 1,   IL6↓, 3,   IL8↓, 1,   Imm↑, 4,   Imm↝, 1,   Macrophages↑, 1,   Neut↑, 1,   NF-kB↓, 3,   NK cell↑, 2,   PD-1↝, 1,   PD-L1↓, 4,   T-Cell↑, 4,   Th1 response↑, 1,   TNF-α↑, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

RANKL↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 1,   BioAv↝, 1,   ChemoSen↑, 1,   Dose↝, 1,   Dose∅, 1,   eff↓, 2,   eff↑, 2,   RadioS↑, 1,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   GutMicro↑, 1,   HER2/EBBR2↓, 1,   IL6↓, 3,   PD-L1↓, 4,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 3,   AntiTum↑, 2,   Appetite↑, 1,   breath↑, 1,   chemoP↑, 1,   ChemoSideEff↓, 1,   hepatoP↑, 1,   OS↑, 5,   OS⇅, 1,   Pain↓, 2,   QoL↑, 1,   radioP↑, 2,   Risk↓, 1,   Sleep↑, 1,   Strength↑, 2,   toxicity↓, 1,   Weight↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

CD8+↑, 12,  
Total Targets: 160

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 1,   lipid-P↓, 1,   NRF2↑, 1,   ROS↓, 1,   SOD↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   glucose↝, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

DNA Damage & Repair(tgid=10) ⓘ

P53↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

mTOR↓, 1,  

Migration(tgid=13) ⓘ

β-Endo↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 2,   NF-kB↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

BMD↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   AntiArt↑, 1,   AntiP↑, 1,   neuroP↑, 1,   OS↑, 1,   toxicity↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 26

Scientific Paper Hit Count for: CD4+, CD4+ T Cells
3 Magnetic Field Rotating
3 Magnetic Fields
2 immunotherapy
1 Silver-NanoParticles
1 Resiquimod
1 Akkermansia
1 Apigenin (mainly Parsley)
1 Caffeine
1 Chlorogenic acid
1 Chrysin
1 Gambogic Acid
1 Hydrogen Gas
1 Honokiol
1 Inulin Prebiotic
1 Licochalcone A
1 Lactoferrin/Talactoferrin
1 Melatonin
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:544  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page